Q32 Bio (QTTB) Competitors $1.97 +0.09 (+4.79%) Closing price 04:00 PM EasternExtended Trading$1.92 -0.04 (-2.28%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. PLRX, ANIX, ONCY, ZNTL, SRZN, VIRI, SCLX, TCRX, ADAG, and QNCXShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), Oncolytics Biotech (ONCY), Zentalis Pharmaceuticals (ZNTL), Surrozen (SRZN), Virios Therapeutics (VIRI), Scilex (SCLX), TScan Therapeutics (TCRX), Adagene (ADAG), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Its Competitors Pliant Therapeutics Anixa Biosciences Oncolytics Biotech Zentalis Pharmaceuticals Surrozen Virios Therapeutics Scilex TScan Therapeutics Adagene Quince Therapeutics Q32 Bio (NASDAQ:QTTB) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Is QTTB or PLRX more profitable? Pliant Therapeutics' return on equity of -73.45% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -2,709.70% -61.16% Pliant Therapeutics N/A -73.45%-55.66% Do analysts rate QTTB or PLRX? Q32 Bio presently has a consensus target price of $12.17, suggesting a potential upside of 517.60%. Pliant Therapeutics has a consensus target price of $8.19, suggesting a potential upside of 428.23%. Given Q32 Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Q32 Bio is more favorable than Pliant Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.08 Does the media prefer QTTB or PLRX? In the previous week, Pliant Therapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 6 mentions for Pliant Therapeutics and 4 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.72 beat Pliant Therapeutics' score of 0.17 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, QTTB or PLRX? Q32 Bio has higher earnings, but lower revenue than Pliant Therapeutics. Q32 Bio is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$1.16M20.72-$47.73M-$4.30-0.46Pliant Therapeutics$1.58M60.22-$210.30M-$3.40-0.46 Do institutionals & insiders hold more shares of QTTB or PLRX? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryPliant Therapeutics beats Q32 Bio on 8 of the 14 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.93M$3.11B$5.67B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-0.4620.3830.5825.12Price / Sales20.72367.51464.55116.64Price / CashN/A42.3037.4059.05Price / Book-1.978.659.096.18Net Income-$47.73M-$54.65M$3.25B$264.89M7 Day Performance20.86%6.59%4.76%2.66%1 Month Performance-5.29%9.57%6.72%3.05%1 Year Performance-94.63%14.06%30.51%25.05% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.8159 of 5 stars$1.97+4.8%$12.17+517.6%-94.8%$22.93M$1.16M-0.4639News CoverageShort Interest ↓PLRXPliant Therapeutics3.908 of 5 stars$1.70+7.6%$13.31+683.1%-86.8%$96.99M$1.58M-0.4790ANIXAnixa Biosciences2.5724 of 5 stars$3.26+8.3%$9.00+176.1%-4.2%$96.96M$210K-8.585ONCYOncolytics Biotech1.8609 of 5 stars$0.88-10.8%$4.33+390.7%-4.1%$96.43MN/A-3.0530Earnings ReportAnalyst ForecastZNTLZentalis Pharmaceuticals2.0426 of 5 stars$1.39+3.7%$8.37+501.9%-48.9%$96.42M$67.43M-0.44160SRZNSurrozen2.8773 of 5 stars$10.71-2.7%$38.50+259.6%+65.6%$94.19M$10.65M-0.4380Positive NewsEarnings ReportAnalyst RevisionVIRIVirios Therapeutics0.1089 of 5 stars$4.85+0.3%$5.00+3.1%+2,635.0%$93.40MN/A-17.965SCLXScilex2.1911 of 5 stars$14.96+11.6%$455.00+2,941.4%-60.3%$93.22M$50.71M-0.5280News CoverageEarnings ReportTCRXTScan Therapeutics3.6818 of 5 stars$1.71+5.6%$7.80+356.1%-67.9%$91.68M$2.82M-1.57100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionADAGAdagene2.9899 of 5 stars$1.95+1.5%$8.00+310.5%-19.9%$90.45M$100K0.00260News CoverageAnalyst ForecastAnalyst RevisionQNCXQuince Therapeutics2.8567 of 5 stars$1.63-3.0%$8.00+390.8%+207.2%$90.09MN/A-1.1760News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Pliant Therapeutics Competitors Anixa Biosciences Competitors Oncolytics Biotech Competitors Zentalis Pharmaceuticals Competitors Surrozen Competitors Virios Therapeutics Competitors Scilex Competitors TScan Therapeutics Competitors Adagene Competitors Quince Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access